Cargando…
Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States
IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857514/ https://www.ncbi.nlm.nih.gov/pubmed/36580313 http://dx.doi.org/10.1001/jamaophthalmol.2022.3225 |
_version_ | 1784873886341398528 |
---|---|
author | Smith, Terry J. Cockerham, Kimberly Lelli, Gary Choudhary, Chitra Taylor, Stephanie Barretto, Naina Enstone, Ashley Oliver, Louisa Lynch, Judah Holt, Robert J. |
author_facet | Smith, Terry J. Cockerham, Kimberly Lelli, Gary Choudhary, Chitra Taylor, Stephanie Barretto, Naina Enstone, Ashley Oliver, Louisa Lynch, Judah Holt, Robert J. |
author_sort | Smith, Terry J. |
collection | PubMed |
description | IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score ≥4, ±diplopia/proptosis) and refined using interviews with US patients with TED (n = 6). Each health state description was validated by interviews with additional TED patient advocates (n = 3) and physician experts (n = 3). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings. MAIN OUTCOMES AND MEASURES: TED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired t tests. RESULTS: A total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia/small proptosis). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies. |
format | Online Article Text |
id | pubmed-9857514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-98575142023-02-17 Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States Smith, Terry J. Cockerham, Kimberly Lelli, Gary Choudhary, Chitra Taylor, Stephanie Barretto, Naina Enstone, Ashley Oliver, Louisa Lynch, Judah Holt, Robert J. JAMA Ophthalmol Original Investigation IMPORTANCE: Thyroid eye disease (TED) results in varying degrees of proptosis and diplopia negatively affecting quality of life (QoL), producing possibly substantial visual changes, disfigurement, and disability. OBJECTIVE: To determine the association of varying TED severities with QoL in a non-TED population by assessing health state utility scores. DESIGN, SETTING, AND PARTICIPANTS: This qualitative study, conducted from April 20, 2020, to April 29, 2021, assessed health states for active, moderate-severe TED, and values were elicited using time trade-off methods. Six health states of varying severity were determined from 2 placebo-controlled clinical trials (171 patients with TED and clinical activity score ≥4, ±diplopia/proptosis) and refined using interviews with US patients with TED (n = 6). Each health state description was validated by interviews with additional TED patient advocates (n = 3) and physician experts (n = 3). Health state descriptions and a QOL questionnaire were piloted and administered to a general population. Visual analog scales (VASs) were also administered to detect concurrence of the findings. MAIN OUTCOMES AND MEASURES: TED health state utility scores and whether they differ from one another were assessed using Shapiro-Wilk, Kruskal-Wallis, pairwise Wilcoxon rank sum, and paired t tests. RESULTS: A total of 111 participants completed time trade-off interviews. The mean (SD) utility value was 0.44 (0.34). The lowest (worse) mean utility value was observed in the most severe disease state (constant diplopia/large proptosis) with 0.30 (95% CI, 0.24-0.36), followed by constant diplopia/small proptosis (0.34; 95% CI, 0.29-0.40), intermittent or inconstant diplopia/large proptosis (0.43; 95% CI, 0.36-0.49), no diplopia/large proptosis (0.46; 95% CI, 0.40-0.52), and intermittent or inconstant diplopia/small proptosis (0.52; 95% CI, 0.45-0.58). The highest (best) mean value, 0.60 (95% CI, 0.54-0.67), was observed for the least severe disease state (no diplopia/small proptosis). CONCLUSIONS AND RELEVANCE: These findings suggest that patients with active, moderate-severe TED may have substantial disutility, with increasing severity of proptosis/diplopia more likely to have detrimental associations with QoL. These health state scores may provide a baseline for determining QoL improvement in these TED health states (utility gains) treated with new therapies. American Medical Association 2022-12-29 2023-02 /pmc/articles/PMC9857514/ /pubmed/36580313 http://dx.doi.org/10.1001/jamaophthalmol.2022.3225 Text en Copyright 2022 Smith TJ et al. JAMA Ophthalmology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the CC-BY-NC-ND License. |
spellingShingle | Original Investigation Smith, Terry J. Cockerham, Kimberly Lelli, Gary Choudhary, Chitra Taylor, Stephanie Barretto, Naina Enstone, Ashley Oliver, Louisa Lynch, Judah Holt, Robert J. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States |
title | Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States |
title_full | Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States |
title_fullStr | Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States |
title_full_unstemmed | Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States |
title_short | Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States |
title_sort | utility assessment of moderate to severe thyroid eye disease health states |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857514/ https://www.ncbi.nlm.nih.gov/pubmed/36580313 http://dx.doi.org/10.1001/jamaophthalmol.2022.3225 |
work_keys_str_mv | AT smithterryj utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT cockerhamkimberly utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT lelligary utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT choudharychitra utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT taylorstephanie utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT barrettonaina utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT enstoneashley utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT oliverlouisa utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT lynchjudah utilityassessmentofmoderatetoseverethyroideyediseasehealthstates AT holtrobertj utilityassessmentofmoderatetoseverethyroideyediseasehealthstates |